Business Context and Reporting Period
This Form 8-K filing by Quoin Pharmaceuticals, Ltd. (QNRX) was submitted on April 6, 2023, reporting an event that occurred on April 5, 2023. The Company is incorporated in Israel and its American Depositary Shares (ADS) trade on The Nasdaq Stock Market LLC.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document is a current report regarding a specific regulatory event rather than a periodic financial report.
Material Changes
The material change reported is a notification from Nasdaq regarding the Company's failure to meet the minimum bid price requirement. Specifically, the closing bid price per ADS (representing 5,000 ordinary shares) remained below $1.00 for 30 consecutive business days, violating Nasdaq Rule 5550(a)(2).
Outlook, Risks, and Management Commentary
- Compliance Period: The Company has been granted an initial 180-day compliance period, ending October 2, 2023, to regain compliance.
- Compliance Criteria: To resolve the issue, the closing bid price per ADS must reach at least $1.00 for a minimum of 10 consecutive business days during the compliance period.
- Contingency: If the Company fails to regain compliance by October 2, 2023, it may be eligible for an additional 180-day grace period. Qualification for this extension requires meeting the market value of publicly held ADSs and all other initial listing standards for The Nasdaq Capital Market, excluding the bid price requirement.
- Risk Disclosure: Management states there can be no assurance that the Company will be able to regain compliance with the minimum bid-price requirement. Failure to do so could result in delisting.
Investor Verification Checklist
- Verify the current trading price of QNRX ADS to assess proximity to the $1.00 threshold.
- Monitor the Company's progress toward the October 2, 2023, compliance deadline.
- Review future filings for any announcements regarding a reverse stock split or other capital structure changes intended to address the bid price deficiency.
- Check for any subsequent Nasdaq communications regarding the Company's listing status.